Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Paclitaxel + Carboplatin for Metastatic Esophageal/Gastric Adenocarcinoma
NCT00107341Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, Gastric cardia adenocarcinoma (GCA), sponsored by Cancer and Leukemia Group B. Started Aug 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaGastric cardia adenocarcinoma (GCA)
Beyond the preview
Go deeper on NCT00107341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107341.